 <h1>Victrelis Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>boceprevir</i></p><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li>Overview</li>
<li><b class="nav-item here">Side Effects</b></li>
<li>Dosage</li>
<li>Professional</li>
<li>Interactions</li>
<li class="nav-more">
More&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewbox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;
</li>
</ul><ul>
<li>Managing Side Effects</li>
</ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about boceprevir. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Victrelis.</p><p><i>Applies to boceprevir: oral capsule</i></p><h3>General</h3><p>This drug must be administered in combination with peginterferon alfa and ribavirin.  The manufacturer product information for peginterferon alfa and ribavirin should be consulted for associated side effects.</p><p></p><p>Serious side effects (including anemia and neutropenia) have been reported in 11% of patients receiving boceprevir (the active ingredient contained in Victrelis) combination therapy compared to 8% of patients receiving peginterferon alfa plus ribavirin alone.  The side effects reported most frequently were fatigue, anemia, nausea, headache, and dysgeusia.  Therapy was discontinued due to side effects in 13% of patients using boceprevir combination therapy and 12% of patients using peginterferon alfa plus ribavirin alone.  The side effects leading to discontinuation most often were anemia and fatigue.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia (up to 50%), decreased hemoglobin (up to 49%), decreased neutrophils (up to 31%), neutropenia (up to 25%)</p><p><b>Common</b> (1% to 10%): Decreased platelets, leukopenia, thrombocytopenia, pancytopenia, agranulocytosis</p><p><b>Uncommon</b> (0.1% to 1%): Hemorrhagic diathesis, lymphadenopathy, lymphopenia</p><p><b>Rare</b> (less than 0.1%): Hemolysis<sup>[Ref]</sup></p><p>Decreased hemoglobin (less than 10 g/dL: 49%; less than 8.5 g/dL: up to 10%), decreased neutrophils (less than 0.75 x 10[9]/L: up to 31%; less than 0.5 x 10[9]/L: up to 8%), and decreased platelets (less than 50 x 10[9]/L: up to 4%; less than 25 x 10[9]/L: less than 1%) have been reported.</p><p></p><p>Agranulocytosis, pancytopenia, and thrombocytopenia have also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Serious acute hypersensitivity reactions (e.g., urticaria, angioedema)<sup>[Ref]</sup></p><h3>Other</h3><p>Sepsis has also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Fatigue (up to 58%), chills (up to 34%), pyrexia (up to 32%), influenza-like illness (up to 23%), asthenia (up to 21%), decreased weight (11%)</p><p><b>Common</b> (1% to 10%): Pain, peripheral edema, chest discomfort, chest pain, malaise, feeling of body temperature change, mucosal dryness</p><p><b>Uncommon</b> (0.1% to 1%): Feeling abnormal, impaired healing, noncardiac chest pain, staphylococcal infection, candidiasis, ear infection, ear discomfort, flushing, pallor, peripheral coldness</p><p><b>Rare</b> (less than 0.1%): Otitis media, sepsis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Mouth ulceration and stomatitis have also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Nausea (up to 46%), dysgeusia (up to 44%), diarrhea (up to 25%), vomiting (up to 20%), dry mouth (up to 15%)</p><p><b>Common</b> (1% to 10%): Abdominal pain, upper abdominal pain, constipation, gastroesophageal reflux disease, hemorrhoids, abdominal discomfort, abdominal distention, anorectal discomfort, aphthous stomatitis, cheilitis, dyspepsia, flatulence, glossodynia, mouth ulceration, oral pain, stomatitis, tooth disorder, oral fungal infection</p><p><b>Uncommon</b> (0.1% to 1%): Lower abdominal pain, gastritis, pancreatitis, anal pruritus, colitis, dysphagia, discolored feces, frequent bowl movements, gingival bleeding, gingival pain, gingivitis, glossitis, dry lip, odynophagia, proctalgia, rectal hemorrhage, salivary hypersecretion, sensitivity of teeth, tongue discoloration, tongue ulceration, gastroenteritis</p><p><b>Rare</b> (less than 0.1%): Pancreatic insufficiency<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 45%), dizziness (up to 19%)</p><p><b>Common</b> (1% to 10%): Hypoesthesia, paresthesia, syncope, amnesia, attention disturbance, memory impairment, migraine, parosmia, tremor, vertigo, tinnitus</p><p><b>Uncommon</b> (0.1% to 1%): Peripheral neuropathy, cognitive disorder, hyperesthesia, lethargy, loss of consciousness, mental impairment, neuralgia, presyncope, deafness, impaired hearing</p><p><b>Rare</b> (less than 0.1%): Cerebral ischemia, encephalopathy<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (up to 34%), irritability (up to 22%), depression (up to 21%), anxiety (12%)</p><p><b>Common</b> (1% to 10%): Affect lability, agitation, libido disorder, altered mood, sleep disorder</p><p><b>Uncommon</b> (0.1% to 1%): Aggression, homicidal ideation, panic attack, paranoia, substance abuse, suicidal ideation, abnormal behavior, anger, apathy, confusional state, mental status changes, restlessness</p><p><b>Rare</b> (less than 0.1%): Bipolar disorder, completed suicide, suicide attempt, auditory hallucination, visual hallucination, psychiatric decompensation<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Alopecia (up to 27%), dry skin (up to 22%), rash (up to 17%)</p><p><b>Common</b> (1% to 10%): Dermatitis, eczema, erythema, hyperhidrosis, night sweats, psoriasis, erythematous rash, macular rash, maculopapular rash, papular rash, pruritic rash, skin lesion, cellulitis, herpes simplex</p><p><b>Uncommon</b> (0.1% to 1%): Photosensitivity reaction, skin ulcer, urticaria, fungal skin infection, onychomycosis, skin infection</p><p><b>Postmarketing reports</b>: Angioedema, drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, exfoliative rash, exfoliative dermatitis, Stevens-Johnson syndrome, toxic skin eruption, toxicoderma<sup>[Ref]</sup></p><p>Urticaria has also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite/anorexia (up to 26%)</p><p><b>Common</b> (1% to 10%): Dehydration, hyperglycemia, hypertriglyceridemia, hyperuricemia</p><p><b>Uncommon</b> (0.1% to 1%): Hypokalemia, appetite disorder, diabetes mellitus, gout, hypercalcemia</p><p><b>Rare</b> (less than 0.1%): Non-acute porphyria</p><p><b>Frequency not reported</b>: Increased uric acid, increased triglycerides, increased cholesterol<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Myalgia (up to 24%), arthralgia (up to 23%)</p><p><b>Common</b> (1% to 10%): Back pain, pain in extremity, muscle spasms, muscular weakness, neck pain</p><p><b>Uncommon</b> (0.1% to 1%): Musculoskeletal chest pain, arthritis, bone pain, joint swelling, musculoskeletal pain<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Pneumonia has also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Exertional dyspnea (up to 11%), cough, dyspnea</p><p><b>Common</b> (1% to 10%): Bronchitis, influenza, sinusitis, epistaxis, nasal congestion, oropharyngeal pain, respiratory tract congestion, sinus congestion, wheezing</p><p><b>Uncommon</b> (0.1% to 1%): Pneumonia, nasopharyngitis, pharyngitis, respiratory tract infection, rhinitis, pleuritic pain, pulmonary embolism, dry throat, dysphonia, increased upper airway secretion, oropharyngeal blistering</p><p><b>Rare</b> (less than 0.1%): Epiglottitis, pleural fibrosis, orthopnea, respiratory failure<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Palpitations, hypotension, hypertension</p><p><b>Uncommon</b> (0.1% to 1%): Cardiac murmur, increased heart rate, tachycardia, arrhythmia, cardiovascular disorder, deep vein thrombosis</p><p><b>Rare</b> (less than 0.1%): Acute myocardial infarction, atrial fibrillation, coronary artery disease, pericarditis, pericardial effusion, venous thrombosis</p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Goiter, hypothyroidism</p><p><b>Uncommon</b> (0.1% to 1%): Hyperthyroidism</p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Pollakiuria, erectile dysfunction</p><p><b>Uncommon</b> (0.1% to 1%): Urinary tract infection, dysuria, nocturia, amenorrhea, menorrhagia, metrorrhagia</p><p><b>Rare</b> (less than 0.1%): Aspermia</p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Dry eye, retinal exudates, blurred vision, visual impairment</p><p><b>Uncommon</b> (0.1% to 1%): Retinal ischemia, retinopathy, abnormal sensation in eye, conjunctival hemorrhage, conjunctivitis, eye pain, eye pruritus, eye swelling, eyelid edema, increased lacrimation, ocular hyperemia, photophobia</p><p><b>Rare</b> (less than 0.1%): Papilledema</p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Hyperbilirubinemia</p><p><b>Rare</b> (less than 0.1%): Cholecystitis</p><h3>Immunologic</h3><p><b>Rare</b> (less than 0.1%): Sarcoidosis</p><h3>Oncologic</h3><p><b>Rare</b> (less than 0.1%): Thyroid neoplasm (nodules)</p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Victrelis (boceprevir)." Schering-Plough Corporation, Kenilworth, NJ. </p><p id="ref_4">4. "Telaprevir (Incivek) and boceprevir (Victrelis) for chronic hepatitis C." Med Lett Drugs Ther 53 (2011): 57-9</p><p id="ref_5">5. Chang MH,  Gordon LA,  Fung HB "Boceprevir: a protease inhibitor for the treatment of hepatitis C." Clin Ther 34 (2012): 2021-38</p><p id="ref_6">6. Rowe IA,  Mutimer DJ "Protease inhibitors for treatment of genotype 1 hepatitis C virus infection." BMJ 343 (2011): d6972</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What are the new drugs for the treatment of hepatitis C?</li>
</ul><h2>More about Victrelis (boceprevir)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>3 Reviews</li>
<li>Drug class: protease inhibitors</li>
<li>FDA Alerts (1)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Victrelis &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Hepatitis C</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>